Moderna, Inc. (NASDAQ:MRNA) is favoured by institutional owners who hold 68% of the company

In this article:

Key Insights

  • Significantly high institutional ownership implies Moderna's stock price is sensitive to their trading actions

  • The top 11 shareholders own 51% of the company

  • Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business

Every investor in Moderna, Inc. (NASDAQ:MRNA) should be aware of the most powerful shareholder groups. We can see that institutions own the lion's share in the company with 68% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute.

Let's take a closer look to see what the different types of shareholders can tell us about Moderna.

View our latest analysis for Moderna

ownership-breakdown
NasdaqGS:MRNA Ownership Breakdown July 13th 2024

What Does The Institutional Ownership Tell Us About Moderna?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Moderna. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Moderna, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
NasdaqGS:MRNA Earnings and Revenue Growth July 13th 2024

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Hedge funds don't have many shares in Moderna. Baillie Gifford & Co. is currently the company's largest shareholder with 12% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 10% and 6.6%, of the shares outstanding, respectively. Furthermore, CEO Stephane Bancel is the owner of 5.5% of the company's shares.

Looking at the shareholder registry, we can see that 51% of the ownership is controlled by the top 11 shareholders, meaning that no single shareholder has a majority interest in the ownership.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.